» Articles » PMID: 31470608

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2019 Sep 1
PMID 31470608
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Skeletal metastases of unknown primary (SMUP) represent a clinical challenge in dealing with patients diagnosed with bone metastases. Management of these patients has improved significantly in the past few years. however, it is fraught with a lack of evidence. While some patients have achieved impressive gains, a more systematic and tailored treatment is required. Nevertheless, in real-life practice, the outlook at the beginning of treatment for SMUP is decidedly somber. An incomplete translational relevance of pathological and clinical data on the mortality and morbidity rate has had unsatisfactory consequences for SMUP patients and their physicians. We examined several approaches to confront the available evidence; three key points emerged. The characterization of the SMUP biological profile is essential to driving clinical decisions by integrating genetic and molecular profiles into a multi-step diagnostic work-up. Nonetheless, a pragmatic investigation plan and therapy of SMUP cannot follow a single template; it must be adapted to different pathophysiological dynamics and coordinated with efforts of a systematic algorithm and high-quality data derived from statistically powered clinical trials. The discussion in this review points out that greater efforts are required to face the unmet needs present in SMUP patients in oncology.

Citing Articles

Decoding the Intricate Landscape of Pancreatic Cancer: Insights into Tumor Biology, Microenvironment, and Therapeutic Interventions.

Argentiero A, Andriano A, Caradonna I, de Martino G, Desantis V Cancers (Basel). 2024; 16(13).

PMID: 39001498 PMC: 11240778. DOI: 10.3390/cancers16132438.


PTH and the Regulation of Mesenchymal Cells within the Bone Marrow Niche.

Liu H, Liu L, Rosen C Cells. 2024; 13(5.

PMID: 38474370 PMC: 10930661. DOI: 10.3390/cells13050406.


Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.

Solimando A, Krebs M, Desantis V, Marziliano D, Caradonna I, Morizio A Biomedicines. 2023; 11(7).

PMID: 37509726 PMC: 10377041. DOI: 10.3390/biomedicines11072087.


Bone metastatic cancer of unknown primary at initial presentation.

Matsuoka M, Onodera T, Yokota I, Iwasaki K, Suzuki Y, Masanari H Clin Transl Oncol. 2023; 26(2):461-467.

PMID: 37395989 DOI: 10.1007/s12094-023-03267-6.


Forging New Therapeutic Targets: Efforts of Tumor Derived Exosomes to Prepare the Pre-Metastatic Niche for Cancer Cell Dissemination and Dormancy.

Bhatia R, Chang J, Munoz J, Walker N Biomedicines. 2023; 11(6).

PMID: 37371709 PMC: 10295689. DOI: 10.3390/biomedicines11061614.


References
1.
Solimando A, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A . JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia. 2017; 32(3):736-743. PMC: 5843918. DOI: 10.1038/leu.2017.287. View

2.
Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S . A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. Cancer Res. 2017; 78(1):129-142. DOI: 10.1158/0008-5472.CAN-16-3507. View

3.
Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A . Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002; 20(24):4679-83. DOI: 10.1200/JCO.2002.04.019. View

4.
Hemminki K, Riihimaki M, Sundquist K, Hemminki A . Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer. 2012; 133(1):182-9. DOI: 10.1002/ijc.27988. View

5.
Body J, Mancini I . Bisphosphonates for cancer patients: why, how, and when?. Support Care Cancer. 2002; 10(5):399-407. DOI: 10.1007/s005200100292. View